Pulmonary Hypertension PBMC
About: Pulmonary Hypertension PBMC samples are collected from clinically confirmed pulmonary hypertension donors and cryopreserved. These PBMCs are ideal for investigating immune dysregulation, inflammatory cytokine production, and gene expression profiles in pulmonary hypertension pathogenesis.
| Lot Number | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73154 | Pulmonary Hypertension | 10M | Caucasian | 74 | Female |
Adempas 2.5mg TID Letairis 10mg QD Uppradi 1600mcg BID Omeprazole 20mg QD Rosuvastatin 10mg QD Cholestipol 2 1mg tablets QD Vitamin b12, D, calcium supplements
|
1 | |||
| 59295 | Pulmonary Hypertension | 5M | African American | 45 | Female |
Plaque-nil 200mg QD IViG Infusions every 3 weeks Lyrica 200mg QD OxyContin 20mg QD Oxycodone 10.325mg QD
|
4 | $765.00 | ||
| 69946 | Pulmonary Hypertension | 50M | Hispanic/Latino | 42 | Female | United States (US) |
Orenitram 5mg Letairis 10 mg Adcirca 20 mg
|
92 | $1,208.00 | |
| 69059 | Pulmonary Hypertension | 50M | Hispanic/Latino | 41 | Female | United States (US) |
Orenitram 0.5 mg 3x/day Letairis 10 mg/1x day Winrevair 1mg/3 weeks, last injection 5/11 Bumex as needed
|
82 | $1,208.00 | |
| 66907 | Pulmonary Hypertension | 50M | Hispanic/Latino | 43 | Female | United States (US) |
Letairis 10 mg 1x/day Adempas 2.5 mg 3x/day Winrevair 1.3 ml/ every 3 weeks, last injection 5/13/25
|
115 | $1,208.00 | |
| 68412 | Pulmonary Hypertension | 50M | Asian/Pacific Islander | 58 | Female | United States (US) |
TYVASO - NEBULIZER BOSENTAN 125 MG- PAH BABY ASPRIN ALDATONE 5 MG MUTLTI VIT
|
84 | $1,208.00 | |
| 55948 | Pulmonary Hypertension | 9M | Caucasian | 70 | Female | United States (US) |
Sildenafil 20mg TID lisinopril 5mg Hydroxychloroquine 200 mg BID pepcid Tylenol PRN O2
|
2 |
High-Quality Pulmonary Hypertension PBMC for Research
Pulmonary Hypertension Human PBMC products are sourced from donors clinically diagnosed with Pulmonary Hypertension and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune dysregulation, inflammatory cytokine production, and gene expression profiles in pulmonary hypertension pathogenesis
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed pulmonary hypertension donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified pulmonary hypertension diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional pulmonary hypertension-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in pulmonary hypertension pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
Pulmonary Hypertension PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
All our samples have self-reported infectious disease testing and verified clinical diagnosis. Many of our samples have the option of electronic medical records provided and our prospective collection offers the opportunity for patient reported outcomes and surveys. Learn more here. https://sanguinebio.com/patient-reported-outcomes-pro-surveys-questionnaires/
1 Answer
YES – Certificate of analysis is available upon request.
1 Answer
Lead times vary from ready to ship inventory to prospective studies.
1 Answer
International shipping is available. We also work with a number of distributors. Contact us to discuss options at learnmore@sanguinebio.com.
1 Answer
We have several ordering methods. You can order directly online with a PO or credit card or contact us to have a sales specialist help with your order. https://sanguinebio.com/request-quote/
1 Answer
You can request a quote on this page or contact us at learnmore@sanguinebio.com. https://sanguinebio.com/request-quote/
1 Answer
NO – no minimum order requirements.
1 Answer
For bulk pricing inquiries, please contact: LearnMore@sanguinebio.com
1 Answer
YES – Fresh leukopaks can be delivered same day in select locations. Often, leukopaks are shipped same day as collection, thus arriving next day.
1 Answer
Contact learnmore@sanguinebio.com for current inventory. The website states “over 150 verified-conditions from ready-to-ship to prospective collections.” View our ready to ship products: https://sanguinebio.com/products/?pro_inventory=inventory
1 Answer
YES – Matched samples across multiple matrices are available, including synovial fluid are available.
0 Answer
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.